Screening practices for late effects in pediatric patients on tyrosine kinase inhibitors.

被引：0

作者：

Smith, Stephanie M.

Sabnis, Himalee S.

Lewis, Rebecca Williamson

Effinger, Karen Elizabeth

Bergsagel, Daniel John

Patterson, Briana

Mertens, Ann C.

Sakamoto, Kathleen

Schapira, Lidia

Castellino, Sharon M.

机构：

[1] Stanford Univ, Dept Pediat, Sch Med, Div Hematol Oncol, Stanford, CA 94305 USA

[2] Childrens Healthcare Atlanta, Dept Pediat, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA

[3] Emory Univ, Atlanta, GA 30322 USA

[4] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA

[5] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA

[6] AFLAC Canc Ctr & Blood Disorders Svc, Atlanta, GA USA

[7] Emory Univ, Sch Med, Dept Pediat, Div Endocrinol, Atlanta, GA USA

[8] Stanford Univ, Stanford, CA 94305 USA

[9] Stanford Canc Inst, Stanford, CA USA

[10] Childrens Healthcare Atlanta, Atlanta, GA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e22527

引用

页数：2

共 50 条

[11] Modulation of CFTR chloride channels by tyrosine kinase inhibitors.
Yang, ICH
Wang, F
Price, EM
Hwang, TC
BIOPHYSICAL JOURNAL, 1996, 70 (02) : WP194 - WP194
[12] Tyrosine kinase signal transduction inhibitors. Clinical trials
Scagliotti, GV
TUMORI JOURNAL, 2002, : S34 - S36
[13] Antibodies and tyrosine kinase inhibitors. It takes two to tango!
Herr D.
Bekes I.
Kreienberg R.
Der Gynäkologe, 2010, 43 (12): : 996 - 1001
[14] Tyrosine kinase inhibitors in pediatric malignancies
Skolnik, Jeffrey M.
Adamson, Peter C.
CANCER INVESTIGATION, 2007, 25 (07) : 606 - 612
[15] Musculoskeletal symptoms in chronic myeloid leukemia patients after stopping tyrosine kinase inhibitors.
Diab, Maria
Jeyakunnar, Ghayathri
Schiffer, Charles Alan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[16] Risk of QTc interval prolongation among cancer patients treated with tyrosine kinase inhibitors.
Abu Rmilah, Anan Abdelmoti
Lin, Grace
Herrmann, Joerg
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[17] Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.
George S.
Desai J.
Current Treatment Options in Oncology, 2002, 3 (6) : 489 - 496
[18] Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors
Tecen-Yucel, Kamer
Bayraktar-Ekincioglu, Aygin
Kilickap, Saadettin
Erman, Mustafa
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2018, 28 (01): : 53 - 60
[19] FcεRI-dependent tyrosine phosphorylation in human mast cells:: Comparative effects of tyrosine kinase and tyrosine phosphatase inhibitors.
Tkaczyk, C
Metcalfe, DD
Gilfillan, AM
FASEB JOURNAL, 2000, 14 (06): : A1245 - A1245
[20] Synthesis and screening of a library of bidentate protein tyrosine phosphatase inhibitors.
Xie, J
Seto, CT
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U135 - U135

← 1 2 3 4 5 →